Publication: Hyperactive androgen receptor in prostate cancer, what does it mean for new therapy concepts?
Loading...
Date
1997
Authors
Culig, Z. ; Hobisch, A. ; Hittmair, A. ; Radmayr, C. ; Peterziel, H. ; Bartsch, G. ; Cato, A.C.B. ; Klocker, H.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Investigations on androgen signaling
alterations in the late stages of prostate cancer revealed
new molecular mechanisms that may be in part responsible
for failure of endocrine therapy. Both primary and
metastatic lesions from prostate cancer express androgen
receptor protein. Amplification of androgen receptor
gene occurs in a subset of prostate cancer patients.
Several point mutations of androgen receptor gene have
been described; they generate receptors which are
functionally activated by androgens, other steroids, and
even by antihormones. The frequency of androgen
receptor mutations may be high in tumor metastases.
Functional activity of androgen receptor is influenced by
nonsteroidal factors, such as peptide growth factors and
second messengers. Thus, prostate cancer cells adapt to
low androgen environment by various mechanisms
utilizing androgen receptor. Therefore, new strategies for
switching off the androgen receptor are needed.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.